E. Gabriela Chiorean, MD, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

Videos

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.


E. Gabriela Chiorean, MD, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer. 

Current Standard Therapies for NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer. 


Standard Treatment Regimens for NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer. 

Choosing RNA or DNA Testing in Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer. 


Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

E. Gabriella Chiorean, MD, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer. 

Prognosis of NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer. 

Prognosis, Rarity of NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, physician, clinical director, Gastrointestinal Medical Oncology, Seattle Cancer Care Alliance, professor of medicine, University of Washington (UW) School of Medicine, clinical research director, Gastrointestinal Medical Oncology, UW Medicine, professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the role of molecular testing in pancreatic cancer.

Molecular testing of genes, proteins, and RNA sequencing has been a significant advance in the management of pancreatic cancer, Chiorean says. Moreover, the National Comprehensive Cancer Network guidelines indicate that all patients diagnosed with pancreatic cancer, as well as first-degree relatives of diagnosed individuals, should undergo germline genetic testing regardless of disease stage. Additionally, patients with locally advanced, unresectable, or metastatic pancreatic cancer should undergo somatic testing via tumor biopsy or liquid biopsy if tumor testing is unavailable, Chiorean says.

Approximately 10% to 20% of patients with pancreatic cancer harbor a molecular alteration that could inform treatment decisions and provide insight into their prognosis, Chiorean says. Opening the door to additional treatment options can optimize survival for this patient population, Chiorean concludes. 

E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.  



E. Gabriela Chiorean, MD, SCCA

Articles

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

Prognosis, Rarity of NRG1+ Pancreatic Cancer

Dr. Chiorean on the Role of Molecular Testing in Pancreatic Cancer